



6 February 2013

MAYNE PHARMA SHARE PURCHASE PLAN RAISED \$5MILLION

Mayne Pharma Group Limited (Mayne Pharma; ASX: MYX) is pleased to announce that its Share Purchase Plan (SPP) successfully closed at 5pm (Melbourne time) on 31 January 2013. Due to overwhelming demand, the SPP was heavily oversubscribed with applications being received from eligible shareholders for approximately \$9.2 million. As the SPP was capped at \$5 million, Mayne Pharma will scale back applications for new shares on a pro rata basis to approximately 55% of the total value of applications received. The excess subscription monies will be refunded to all applicants as soon as reasonably practicable.

As previously announced, the funds raised by the SPP will be used to accelerate the development, registration and marketing of Mayne Pharma's existing product pipeline.

The new shares to be issued under the SPP will rank equally with existing Mayne Pharma shares in all respects from the date of their issue. The new shares are expected to be issued on 8 February 2013 and commence trading on the ASX on a normal settlement basis on 11 February 2013.

If you applied for shares under the SPP, you should confirm your holding before trading any new shares you believe you have acquired under the SPP.

Mayne Pharma has also raised approximately \$0.136 million by way of a placement of new shares to US Mayne Pharma shareholders on substantially the same terms as the SPP.

The Board thanks shareholders for their ongoing support of Mayne Pharma.

-ENDS-

For further information contact:

Scott Richards (CEO)	08 8209 2410
Lisa Pendlebury (Investor Relations)	0419 548 434, lisa.pendlebury@maynepharma.com

NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS

This document may not be released or distributed in the United States. This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. Any securities described in this document have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the US Securities Act and applicable US state securities laws.